Join
Live feed
·
PRReleasevia Quantisnow
Eli Lilly and Company logo

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

ByQuantisnow·Wall Street's wire, on your screen.
LLY· Eli Lilly and Company
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LLY (Eli Lilly and Company) and more on Quantisnow.